Steroids in PARDS: Indications and Dosing
In pediatric acute respiratory distress syndrome (PARDS), systemic corticosteroids should be considered for early moderate-to-severe disease (within 14 days of onset, PaO₂/FiO₂ <200 or SpO₂/FiO₂ equivalent), using methylprednisolone 1-2 mg/kg/day as a prolonged course with strict infection surveillance.
Clinical Decision Framework
When to Initiate Steroids
The evidence supports corticosteroid use in PARDS based on adult ARDS guidelines, as pediatric-specific data remains limited 1, 2. Key criteria include:
- Timing window: Within 14 days of ARDS onset (preferably <72 hours for optimal response) 1
- Severity threshold: Moderate-to-severe disease with PaO₂/FiO₂ <200 1
- Disease phase: Early ARDS when fibroproliferation is still cellular and responsive to lower steroid doses 1
Critical caveat: Initiation >14 days after ARDS onset may be associated with harm and should be avoided 3.
Recommended Dosing Regimen
Based on extrapolation from adult data and limited pediatric experience:
- Agent: Methylprednisolone (preferred based on trial data) 4, 2
- Initial dose: 1 mg/kg/day divided every 6 hours or as continuous infusion 1, 2
- Escalation: Increase to 2 mg/kg/day if no improvement after 7-9 days 4, 5
- Duration: Prolonged course (typically 2-4 weeks), not short high-dose pulses 1, 5
- Discontinuation: Stop at extubation or taper gradually once improvement occurs 3, 5
The continuous infusion approach may prevent glycemic variability in pediatric patients 2.
Evidence Strength and Limitations
The recommendation relies heavily on adult ARDS data, as pediatric-specific randomized trials are lacking 2, 6. Adult guidelines show that corticosteroids reduce mechanical ventilation duration by approximately 7 days and may reduce mortality by 7-11% in moderate-to-severe ARDS 1. However, the certainty of evidence is moderate at best, and pediatric extrapolation requires caution 6.
Important divergence: While older adult studies used high-dose short courses (30 mg/kg methylprednisolone), current evidence supports lower doses (1-2 mg/kg/day) given for prolonged periods 7. The high-dose approach is now considered hazardous and not indicated 5.
Mandatory Safety Measures
Corticosteroid use in PARDS requires:
- Strict infection surveillance: Monitor closely for bacterial, fungal, and opportunistic infections 3, 5, 2
- Avoid neuromuscular blockade: When possible, as combined use increases complications 5
- Metabolic monitoring: Watch for hyperglycemia, particularly with continuous infusion 2
- Gradual tapering: Stepwise dose reduction to prevent rebound inflammation 5
Absolute Contraindications
Do not use corticosteroids when:
- ARDS onset >14 days ago (late/fibrotic phase) 3, 1
- Active uncontrolled fungal infection 8, 9
- High viral load in viral pneumonitis 9
- Recent surgical anastomosis 9
Practical Implementation
For a child with PARDS meeting criteria:
- Confirm timing: <14 days from onset, preferably <72 hours
- Verify severity: PaO₂/FiO₂ <200 or SpO₂/FiO₂ equivalent
- Rule out contraindications: Screen for active infections, recent surgery
- Start methylprednisolone: 1 mg/kg/day divided q6h or continuous infusion
- Monitor daily: Infection signs, glucose, ventilator parameters
- Reassess at 7-9 days: If no improvement, increase to 2 mg/kg/day
- Taper when improving: Gradual reduction once extubated or clinically better
The evidence for PARDS-specific steroid use remains limited, with most recommendations extrapolated from adult data 2, 10, 6. However, given the high mortality of untreated severe PARDS and the consistent signal for benefit in adult studies, a trial of corticosteroids is reasonable in appropriately selected pediatric patients with rigorous safety monitoring 1, 2.